TRK inhibition in soft tissue sarcomas: A comprehensive review.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Clinical Trials as Topic
Drug Resistance, Neoplasm
/ genetics
Genetic Testing
Humans
Molecular Targeted Therapy
Oncogene Proteins, Fusion
/ antagonists & inhibitors
Protein Kinase Inhibitors
/ pharmacology
Receptor Protein-Tyrosine Kinases
/ antagonists & inhibitors
Sarcoma
/ diagnosis
Treatment Outcome
Cancer
Entrectinib
Fusion
Larotrectinib
NTRK
Soft tissue sarcomas
Journal
Seminars in oncology
ISSN: 1532-8708
Titre abrégé: Semin Oncol
Pays: United States
ID NLM: 0420432
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
26
09
2019
revised:
27
02
2020
accepted:
27
02
2020
pubmed:
24
3
2020
medline:
15
5
2020
entrez:
24
3
2020
Statut:
ppublish
Résumé
Soft-tissue sarcomas (STS) are a group of rare mesenchymal tumors that constitutes ∼1% of all solid tumors. It remains a rare tumor which lacks effective treatment options. Precision oncology may be of interest in this regard by identifying potential targets for emerging novel therapies. Neurotrophic receptor tyrosine kinase (NTRK) fusions are rare oncogenic driver mutations found in a broad range of common and rare tumor subtypes including STS. The recent approvals of NTRK inhibitors (larotrectinib and entrectinib) represent new therapeutic options in the drug armamentarium especially valuable in advanced STS given the paucity of treatment options and the generally poor prognosis of these tumors. We review the methods used to detect NTRK fusions in STS with focus on incidence, diagnosis and management of these rare and intriguing oncogenic targets.
Identifiants
pubmed: 32201016
pii: S0093-7754(20)30011-7
doi: 10.1053/j.seminoncol.2020.02.009
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Oncogene Proteins, Fusion
0
Protein Kinase Inhibitors
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-84Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.